JPWO2020020281A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020020281A5 JPWO2020020281A5 JP2020552889A JP2020552889A JPWO2020020281A5 JP WO2020020281 A5 JPWO2020020281 A5 JP WO2020020281A5 JP 2020552889 A JP2020552889 A JP 2020552889A JP 2020552889 A JP2020552889 A JP 2020552889A JP WO2020020281 A5 JPWO2020020281 A5 JP WO2020020281A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- antibody
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 36
- 239000012634 fragment Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2024027487A JP2024063083A (ja) | 2018-07-25 | 2024-02-27 | 抗tigit抗体及びその使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810823583 | 2018-07-25 | ||
CN201810823583.6 | 2018-07-25 | ||
PCT/CN2019/097665 WO2020020281A1 (zh) | 2018-07-25 | 2019-07-25 | 抗tigit抗体及其用途 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024027487A Division JP2024063083A (ja) | 2018-07-25 | 2024-02-27 | 抗tigit抗体及びその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021532058A JP2021532058A (ja) | 2021-11-25 |
JPWO2020020281A5 true JPWO2020020281A5 (enrdf_load_stackoverflow) | 2022-07-28 |
JP7524065B2 JP7524065B2 (ja) | 2024-07-29 |
Family
ID=69181312
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020552889A Active JP7524065B2 (ja) | 2018-07-25 | 2019-07-25 | 抗tigit抗体及びその使用 |
JP2024027487A Withdrawn JP2024063083A (ja) | 2018-07-25 | 2024-02-27 | 抗tigit抗体及びその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2024027487A Withdrawn JP2024063083A (ja) | 2018-07-25 | 2024-02-27 | 抗tigit抗体及びその使用 |
Country Status (12)
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
WO2021147854A1 (zh) * | 2020-01-21 | 2021-07-29 | 信达生物制药(苏州)有限公司 | 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途 |
CN114507284B (zh) * | 2020-05-09 | 2023-05-26 | 华博生物医药技术(上海)有限公司 | 抗tigit的抗体、其制备方法和应用 |
PH12022553257A1 (en) | 2020-06-02 | 2024-02-19 | Arcus Biosciences Inc | Antibodies to tigit |
EP4168118A1 (en) | 2020-06-18 | 2023-04-26 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
WO2022063100A1 (zh) * | 2020-09-22 | 2022-03-31 | 南京圣和药业股份有限公司 | 抗tigit抗体及双抗体和它们的应用 |
TWI815220B (zh) * | 2020-11-23 | 2023-09-11 | 大陸商廣東菲鵬制藥股份有限公司 | 抗tigit抗體或其抗原結合片段及其生產方法與應用,以及包含其的核酸、載體、細胞、藥物組合物及試劑盒 |
KR20220082776A (ko) * | 2020-12-10 | 2022-06-17 | 주식회사 유틸렉스 | 항-tigit 항체 및 이의 용도 |
JP2024514974A (ja) * | 2021-04-26 | 2024-04-03 | メモリアル スローン-ケタリング キャンサー センター | Adgre2及び/またはclec12aを標的とするキメラ受容体及びその使用 |
KR102500845B1 (ko) * | 2021-05-10 | 2023-02-17 | 메디맵바이오 주식회사 | 항-tigit 항체 및 이의 용도 |
JP2024527049A (ja) | 2021-07-28 | 2024-07-19 | ジェネンテック, インコーポレイテッド | がんを治療するための方法及び組成物 |
KR20240043786A (ko) * | 2021-08-09 | 2024-04-03 | 바이오세우스 인크. | 항-tigit 항체 및 이의 용도 |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023108609A1 (en) * | 2021-12-17 | 2023-06-22 | Shanghai Nigene Biological Science And Technology Co., Ltd. | Tigit antibodies and uses thereof |
WO2023125941A1 (zh) * | 2021-12-31 | 2023-07-06 | 南京维立志博生物科技有限公司 | Tigit单域抗体以及基于其的双特异性抗体 |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
JP2025523387A (ja) | 2022-06-07 | 2025-07-23 | ジェネンテック, インコーポレイテッド | 抗pd-l1アンタゴニストおよび抗tigitアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法 |
TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
GB9108652D0 (en) | 1991-04-23 | 1991-06-12 | Antisoma Ltd | Immunoreactive compounds |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
CA2144043C (en) | 1992-09-16 | 2005-01-18 | Dennis R. Burton | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
JP3919830B2 (ja) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | 抗ネコヘルペスウイルス−1組換え抗体および該抗体をコードする遺伝子断片 |
WO1995018634A1 (en) | 1994-01-04 | 1995-07-13 | The Scripps Research Institute | Human monoclonal antibodies to herpes simplex virus and methods therefor |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
AU3369999A (en) | 1998-04-02 | 1999-10-25 | Genentech Inc. | Antibody variants and fragments thereof |
GB9814383D0 (en) | 1998-07-02 | 1998-09-02 | Cambridge Antibody Tech | Improvements relating to antibodies |
WO2000005266A1 (en) | 1998-07-21 | 2000-02-03 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Anti hepatitis c virus antibody and uses thereof |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
SE0401751L (sv) | 2004-07-05 | 2005-11-15 | Svensk Roekgasenergi Intressen | Förfarande och anordning för avskiljning av föroreningar ur ett gasflöde |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AU2006247591B2 (en) | 2005-05-12 | 2011-12-15 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
JP5933894B2 (ja) | 2007-09-14 | 2016-06-15 | アディマブ, エルエルシー | 合理的に設計された、合成抗体ライブラリおよびその使用 |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
RU2598248C2 (ru) | 2009-04-02 | 2016-09-20 | Роше Гликарт Аг | Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab |
CA2757931C (en) | 2009-04-07 | 2019-03-26 | Roche Glycart Ag | Trivalent, bispecific antibodies |
WO2010136172A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
WO2012009568A2 (en) | 2010-07-16 | 2012-01-19 | Adimab, Llc | Antibody libraries |
HRP20201404T1 (hr) | 2013-07-16 | 2020-11-27 | F. Hoffmann - La Roche Ag | Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita |
CR20160500A (es) | 2014-03-31 | 2016-12-14 | Genentech Inc | Anticuerpos anti-ox40 y métodos de uso |
IL250583B (en) * | 2014-08-19 | 2022-07-01 | Merck Sharp & Dohme | Anti-tigit antibodies |
SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
JP6976241B2 (ja) * | 2015-08-14 | 2021-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗tigit抗体 |
CN108137691B (zh) * | 2015-09-02 | 2021-10-19 | 耶路撒冷希伯来大学伊萨姆研究发展有限公司 | 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体 |
CN113956358A (zh) * | 2015-09-25 | 2022-01-21 | 豪夫迈·罗氏有限公司 | 抗tigit抗体和使用方法 |
RU2020124191A (ru) * | 2015-10-01 | 2020-08-27 | Потенза Терапевтикс, Инк. | Анти-tigit антиген-связывающие белки и способы их применения |
WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
JP7109382B2 (ja) * | 2016-03-04 | 2022-07-29 | ジェイエヌ バイオサイエンシーズ エルエルシー | Tigitに対する抗体 |
-
2019
- 2019-07-25 BR BR112021001201-0A patent/BR112021001201A2/pt unknown
- 2019-07-25 AU AU2019310803A patent/AU2019310803B2/en active Active
- 2019-07-25 SG SG11202100746WA patent/SG11202100746WA/en unknown
- 2019-07-25 US US16/965,687 patent/US11370837B2/en active Active
- 2019-07-25 JP JP2020552889A patent/JP7524065B2/ja active Active
- 2019-07-25 CN CN201980022679.5A patent/CN112135626B/zh active Active
- 2019-07-25 CA CA3092456A patent/CA3092456C/en active Active
- 2019-07-25 WO PCT/CN2019/097665 patent/WO2020020281A1/zh not_active Application Discontinuation
- 2019-07-25 KR KR1020207028253A patent/KR20210040827A/ko not_active Withdrawn
- 2019-07-25 TW TW108126351A patent/TWI754157B/zh active
- 2019-07-25 EP EP19842191.9A patent/EP3838289A4/en not_active Withdrawn
-
2021
- 2021-01-29 ZA ZA2021/00676A patent/ZA202100676B/en unknown
-
2024
- 2024-02-27 JP JP2024027487A patent/JP2024063083A/ja not_active Withdrawn